Bavarian Nordic

    [td_text_with_title custom_title=”Company description”]Bavarian Nordic is a biopharmaceutical company focused on the development and manufacturing of cancer immunotherapies and vaccines for infectious diseases.[/td_text_with_title]

    Posts not found

    [td_text_with_title custom_title=”Latest post”]

    Potential Combination Strategies for Active Immunotherapy in Prostate Cancer

    From Bavarian Nordic  


    Kerrisdale Advisers LLC short 2,23 % Bavarian Nordic A/S

    Kerrisdale Advisers LLC has build up a big short position in Bavarian Nordic as of june 23.



    Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales KVISTGAARD, Denmark and NEW YORK, March 4, 2015 – Bavarian Nordic (OMX: BAVA, OTC: BVNRY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today an […]

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Bavarian Nordic is a biotechnology company specializing in research, development and manufacture of active cancer immunotherapies and vaccines for infectious diseases. The company is headquartered in Kvistgaard, Denmark (a town in Helsingør Municipality), where it also operates a commercial-scale manufacturing facility. The company has a research and development facility in Martinsried, Germany and an office in Morrisville, North Carolina.

    The company uses viral vectors in its research and development.



    MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells,[4] contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicating smallpox vaccine, Imvamune, it is approved in Canada[5] and in the European Union, where it is marketed as Imvanex.[6] The vaccine is being supplied for emergency use to the U.S. Strategic National Stockpile as well as other government stockpiles. Registration studies for the approval in the U.S. are currently underway.


    A second poxvirus-based technology is employed in most of the company’s cancer immunotherapies, and was in-licensed as part of a collaboration with the National Cancer Institute (NCI). Vaccinia-fowlpox-TRICOM is a sequential prime-boost therapy based on vaccinia and fowlpox in combination with three co-stimulatory molecules (TRICOM). The poxvirus-based immunotherapy can be modified to encode different tumor-associated antigens such as Prostate-specific antigen (PSA), Carcinoembryonic antigen (CEA) and/or Mucin 1 (MUC1), which are all tumor markers that are overexpressed in various cancers. This technology forms the basis of the company’s lead oncology product candidates, Prostvac and CV-301. Prostvac is an active immunotherapy candidate, currently the subject of a global Phase 3 clinical study “PROSPECT”[7] in men with asymptomatic or minimally symptomatic castration-resistant prostate cancer.

    Ebola vaccine development and production

    The company has worked for several years with the NIAID[8] on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of the Janssen Pharmaceuticals Companies of Johnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa.[9][10][11] In January 2015, the company had produced the first 400,000 doses of the vaccine and the first clinical trial of the vaccine regimen was initiated in the UK, with additional trials planned in the US and Africa.[12]


    Bavarian Nordic's pipeline, as of June 2016.[13]

    Product Indication Phase
    Imvanex smallpox Approved
    Prostvac prostate cancer III
    MVA-BN Filo Ebola and Marburg virus III
    CV-301 lung cancer II
    MVA-BN Brachyury solid tumors I
    MVA-BN HPV Chronic HPV infection Preclinical

    In addition, the company has multiple pre-clinical projects based on its MVA-BN technology targeting infectious diseases.

    Bavarian Nordic is a member of the Alliance for Biosecurity, a group of companies that work towards preventing and treating severe infectious diseases, especially those that present global security challenges.[14]


    1. ^ "Management". Bavarian Nordic. Retrieved 2014-10-29. [self-published source]
    2. ^ "Board of Directors". Bavarian Nordic. Archived from the original on 2015-04-07. Retrieved 2015-04-07. [self-published source]
    3. ^ "Annual Report 2016" (PDF). Bavarian Nordic. Retrieved 2017-03-20. [self-published source]
    4. ^ Kennedy JS, Greenberg RN (9 January 2014). "IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine". Expert Reviews of Vaccines. 8 (1): 13–24. doi:10.1586/14760584.8.1.13. PMID 19093767. (Subscription required (help)). 
    5. ^ "Products for Human Use. Submission #144762". Register of Innovative Drugs. Health Canada. 13 June 2014. 144762 (Submission Number). Archived from the original on 17 June 2014. Retrieved 2014-06-26. 
    6. ^ "Imvanex". Human Medicines. European Medicines Agency. 27 May 2016. Retrieved 2016-06-12. 
    7. ^ "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)". U.S. National Institutes of Health. Retrieved 2014-06-26. 
    8. ^ "Infectious Diseases: Filovirus Vaccine". Bavarian Nordic. Retrieved 2014-10-29. 
    9. ^ "Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN® Ebola Vaccine". Bavarian Nordic. 2014-10-22. Retrieved 2014-10-29. 
    10. ^ "BRIEF-Bavarian Nordic to expand collaboration with Janssen". reuters-brief. Reuters. 2014-10-23. Retrieved 2014-10-29. 
    11. ^ "Johnson & Johnson plans Ebola vaccine testing". AP News. 2014-10-22. Archived from the original on 2014-10-31. Retrieved 2014-10-29. 
    12. ^ "J&J, Bavarian Nordic start clinical tests in Ebola vaccine race". Reuters. Reuters. 2015-01-06. Retrieved 2015-01-12. 
    13. ^ "Pipeline". Bavarian Nordic. Retrieved 2016-06-17. 
    14. ^ "Alliance for Biosecurity". Alliance for Biosecurity. Retrieved 2017-02-02. 

    External links